BIODOL Therapeutics is a spin-off from the Laboratoire d’Innovation Thérapeutique (Dr Didier Rognan, UMR 7200) resulting from a collaboration with the Institute for Neurosciences, Montpellier.
This company won BpiFrance’s lab competition and was considered by the magazine Challenges to be one of the top 100 French start-ups in which to invest in 2018. BIODOL develops the first specific treatment for neuropathic pain using its patented technology based on extracellular inhibitors of the tyrosine kinase receptor FLT3. Interaction between FLT3 and the mu opioid receptor opens the way for application of its FLT3 inhibitors to all types of chronic pain, when administered in combination with opioids. The first clinical studies are scheduled for 2021-2022.